文献速递泌尿生殖腹部技术与安全CT

住院急性肾损伤患者静脉注射碘对比剂真的有害吗:倾向性评分匹配研究

Is intravenous iodinated contrast medium administration really harmful in hospitalized acute kidney injury patients: a propensity score-matched study.
PubMed 文献 · Eur Radiol · 2021-08-03

本回顾性倾向性评分匹配研究纳入住院急性肾损伤(AKI)患者,比较接受增强CT与平扫CT者7天和30天内的肾功能恶化、新发肾脏替代治疗(RRT)及死亡率。经1:1匹配后共1172对,两组各项结局均无显著差异。结论认为AKI期间静脉注射碘对比剂不增加上述风险。

要点

  • 住院AKI患者静脉注射碘对比剂后7天和30天肾功能恶化、新发RRT及死亡率与平扫组无显著差异。
  • 即使基线血肌酐较高或多次CT检查,碘对比剂对不良结局的影响也很小。
  • AKI期间不应仅因肾功能恶化风险而常规拒绝增强CT检查。

核心结论

  • AKI期间静脉注射碘对比剂不增加7天和30天肾功能恶化、新发RRT诱导及死亡风险。

研究设计与样本

  • 从1336例暴露于碘对比剂和2724例未暴露者中经1:1匹配生成1172对。
  • 比较CT后7天和30天的肾功能恶化、新发RRT诱导及死亡率。

诊断标准与关键数值

  • 肾功能恶化:7天8% vs 9.0%(OR 0.83,95%CI 0.62-1.11),30天5.1% vs 5.4%(OR 0.93,95%CI 0.64-1.34)。
  • 新发RRT诱导:7天2.3% vs 3.3%(OR 0.72,95%CI 0.43-1.18),30天4.2% vs 4.5%(OR 0.95,95%CI 0.64-1.41)。
  • 死亡率:7天3.9% vs 4.8%(OR 0.83,95%CI 0.56-1.22),30天9.0% vs 10.2%(OR 0.88,95%CI 0.68-1.15)。

临床应用与阅片要点

  • 对于住院AKI患者,不应仅因担心肾功能恶化而避免必要的静脉碘对比剂增强CT检查。
  • 在AKI诊断后7天内行增强CT时,可参考本研究发现与临床团队沟通对比剂使用风险。

局限性

  • 回顾性研究设计可能存在选择偏倚和混杂因素。
  • 单中心研究,结论外推需谨慎。
  • 原文未报告其他明确局限。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

OBJECTIVES: To evaluate the effects of intravenous iodinated contrast medium (ICM) administration on the deterioration of renal function (DRF), new renal replacement therapy (RRT) induction and mortality of hospitalized acute kidney injury (AKI) patients.

METHODS: Adult hospitalized patients undergoing a contrast-enhanced or unenhanced CT scan within 7 days after AKI diagnosis from January 2015 to December 2019 were identified in this retrospective study. Propensity score matching was performed. Outcomes in 7 and 30 days after CT scan were compared between the contrast and non-contrast groups. Additional analyses were also performed in patients stratified by SCr levels at AKI diagnosis, times and time of CT scan, and in patients without chronic kidney disease or RRT requirement prior to CT scan.

RESULTS: In total, 1172 pairs were generated after 1:1 propensity score matching from 1336 cases exposed to ICM and 2724 unexposed. No significant differences were found in the outcomes between the two groups: DRF, 7.8% vs 9.0% (odds ratio (OR) 0.83, 95% confidence interval (CI) 0.62-1.11) in 7 days, 5.1% vs 5.4% (OR 0.93, 95%CI 0.64-1.34) in 30 days; new RRT induction, 2.3% vs 3.3% (OR 0.72,95%CI 0.43-1.18) in 7 days, 4.2% vs 4.5% (OR 0.95,95%CI 0.64-1.41) in 30 days; and mortality, 3.9% vs 4.8% (OR 0.83,95%CI 0.56-1.22) in 7 days, 9.0% vs 10.2% (OR 0.88,95%CI 0.68-1.15) in 30 days. Subset analyses showed similar results.

CONCLUSION: Intravenous ICM administration during AKI duration did not increase the risks of DRF, new RRT induction, and mortality in 7 and 30 days after CT scan.

KEY POINTS: • Intravenous ICM administration in hospitalized AKI patients does not increase the risks of deterioration of renal function, RRT induction, and mortality in 7 and 30 days after CT scan. • The effects of intravenous ICM on adverse outcomes are minimal even in AKI patients with high level of SCr values or multiple CT scans.

来源:Eur Radiol,查看原文。版权归原作者所有。

引用

  1. Yan P, Zhang NY, Luo XQ, et al. Is intravenous iodinated contrast medium administration really harmful in hospitalized acute kidney injury patients: a propensity score-matched study. Eur Radiol. 2021. PMID: 34342692. doi:10.1007/s00330-021-08192-2

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。